Emma S Guns

Summary

Affiliation: University of British Columbia
Country: Canada

Publications

  1. ncbi Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models
    Xiaowei Xie
    Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    J Urol 175:1926-31. 2006
  2. ncbi Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer
    Jennifer A Locke
    Department of Urologic Sciences, University of British Columbia, The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada
    Cancer Res 68:6407-15. 2008
  3. ncbi Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts
    Jonathan C Low
    Urologic Sciences, The Prostate Center at Vancouver General Hospital, 2660 Oak Street, Vancouver, BC, Canada V6H 3Z4
    Cancer Chemother Pharmacol 60:821-9. 2007
  4. ncbi Lycopene differentially induces quiescence and apoptosis in androgen-responsive and -independent prostate cancer cell lines
    Nikita I Ivanov
    Prostate Research Centre at Vancouver General Hospital, University of British Columbia, 2660 Oak Street, Vancouver, BC, Canada V6T 1Z4
    Clin Nutr 26:252-63. 2007
  5. ncbi P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells
    Matthew N Fedoruk
    The Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada
    Prostate 59:77-90. 2004
  6. ncbi pH modulation using CsCl enhances therapeutic effects of vitamin D in LNCaP tumor bearing mice
    Emma S Guns
    The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada
    Prostate 64:316-22. 2005
  7. ncbi Evaluation of the antiproliferative effects of Essiac on in vitro and in vivo models of prostate cancer compared to paclitaxel
    Andy Eberding
    Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, V6H 3Z6, Canada
    Nutr Cancer 58:188-96. 2007
  8. ncbi Drug Insight: lycopene in the prevention and treatment of prostate cancer
    Emma S Guns
    Department of Surgery, University of British Columbia, Canada
    Nat Clin Pract Urol 2:38-43. 2005
  9. ncbi Bioactive compounds from Rhodiola rosea (Crassulaceae)
    Dong Sheng Ming
    Department of Botany, University of British Columbia, Vancouver, Canada
    Phytother Res 19:740-3. 2005
  10. ncbi Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A:Cholesterol Acyltransferase (ACAT)
    Jennifer A Locke
    Department of Urologic Sciences, University of British Columbia, The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada
    Prostate 68:20-33. 2008

Collaborators

  • Lawrence D Mayer
  • K M Wasan
  • Martin Gleave
  • Piotr Kozlowski
  • Andy Eberding
  • Jennifer A Locke
  • Colleen C Nelson
  • Catherine A Wood
  • Nikita I Ivanov
  • Jonathan C Low
  • Candice Madera
  • Ladan Fazli
  • Sherwin Xie
  • Xiaowei Xie
  • Dong Sheng Ming
  • Matthew N Fedoruk
  • Hans H Adomat
  • Amy A Lubik
  • Stephen C Hendy
  • Susan L Ettinger
  • Carlos G Leon
  • Paul S Rennie
  • Simon P Cowell
  • Hans Adomat
  • Paula N Brown
  • Michael E Cox
  • Paula Brown
  • Larry Goldenberg
  • William Jia
  • Brian J Hillhouse
  • Selvarani Vimalanathan
  • G H Neil Towers

Detail Information

Publications10

  1. ncbi Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models
    Xiaowei Xie
    Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    J Urol 175:1926-31. 2006
    ..Conversely combining Rh2 with mitoxantrone appears to elicit no benefit. Therefore, combination therapy using chemotherapy and Rh2 requires further investigation...
  2. ncbi Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer
    Jennifer A Locke
    Department of Urologic Sciences, University of British Columbia, The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada
    Cancer Res 68:6407-15. 2008
    ..This evidence suggests that de novo androgen synthesis may be a driving mechanism leading to CRPC progression following castration...
  3. ncbi Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts
    Jonathan C Low
    Urologic Sciences, The Prostate Center at Vancouver General Hospital, 2660 Oak Street, Vancouver, BC, Canada V6H 3Z4
    Cancer Chemother Pharmacol 60:821-9. 2007
    ..The purpose of this study was to assess the therapeutic and toxicological effects of cesium chloride (CsCl) administration in mice bearing prostate cancer tumors...
  4. ncbi Lycopene differentially induces quiescence and apoptosis in androgen-responsive and -independent prostate cancer cell lines
    Nikita I Ivanov
    Prostate Research Centre at Vancouver General Hospital, University of British Columbia, 2660 Oak Street, Vancouver, BC, Canada V6T 1Z4
    Clin Nutr 26:252-63. 2007
    ..Our study investigates the molecular mechanism underlying anti-cancer activity of lycopene-based products in androgen-responsive (LNCaP) and androgen-independent (PC3) cells...
  5. ncbi P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells
    Matthew N Fedoruk
    The Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada
    Prostate 59:77-90. 2004
    ..The biological consequences of increased P-gp expression are decreased androgen accumulation and a corresponding decrease in androgen-regulated transcriptional activity and PSA gene expression...
  6. ncbi pH modulation using CsCl enhances therapeutic effects of vitamin D in LNCaP tumor bearing mice
    Emma S Guns
    The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada
    Prostate 64:316-22. 2005
    ..CONCLUSIONS: The data presented in this manuscript is the first report of chemosensitization by in vivo pH modulation using CsCl in mice bearing prostate or any other tumor xenograft...
  7. ncbi Evaluation of the antiproliferative effects of Essiac on in vitro and in vivo models of prostate cancer compared to paclitaxel
    Andy Eberding
    Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, V6H 3Z6, Canada
    Nutr Cancer 58:188-96. 2007
    ..Ki-67 and PCNA expression was analyzed in treated tumors, but no difference in expression of either marker was observed. These evaluations suggest Essiac has no marked antiproliferative effect on the models tested...
  8. ncbi Drug Insight: lycopene in the prevention and treatment of prostate cancer
    Emma S Guns
    Department of Surgery, University of British Columbia, Canada
    Nat Clin Pract Urol 2:38-43. 2005
    ..The scope and extent of scientific evidence accrued on lycopene and tomato extracts, reported molecular mechanisms of action, and its potential impact on the incidence and severity of prostate cancer are discussed...
  9. ncbi Bioactive compounds from Rhodiola rosea (Crassulaceae)
    Dong Sheng Ming
    Department of Botany, University of British Columbia, Vancouver, Canada
    Phytother Res 19:740-3. 2005
    ..Cytotoxicity studies of 1 and 2 also displayed activity against the prostate cancer cell line with IC(50) values of 50 microg/mL and 80 microg/mL, respectively...
  10. ncbi Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A:Cholesterol Acyltransferase (ACAT)
    Jennifer A Locke
    Department of Urologic Sciences, University of British Columbia, The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada
    Prostate 68:20-33. 2008
    ..The objective of this work was to determine the effect of an androgen agonist, R1881, on intracellular cholesterol synthesis and esterification in androgen-sensitive (AS) prostate cancer (LNCaP) cells...